Kyprolis (carfilzomib) is a proteasome inhibitor used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. This medication works by blocking the action of proteasomes, which are enzyme complexes that break down proteins within cells. By inhibiting proteasomes, Kyprolis disrupts the cellular processes of cancer cells, leading to their death.
